Home2022-11-17T21:56:16+00:00

Tomorrow’s enteric coatings made from nature’s materials

Our mission is to develop effective gastro-resistant enteric coatings for oral formulations of sensitive pharmaceuticals

Oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals

Apillet has a PCT patent covering a novel specialized encapsulation technology which currently is being developed into a gastro-resistant enteric encapsulation. The technology is based solely on biocompatible non-toxic ingredients and is suitable for the development of a broad range of new pharmaceutical products.

Apillet has a PCT patent covering a novel specialized encapsulation technology which currently is being developed into a gastro-resistant enteric encapsulation. The technology is based solely on biocompatible non-toxic ingredients and is suitable for the development of a broad range of new pharmaceutical products.

Latest News

Apillet participated in the 14th International Conference and Exhibition on Nutraceuticals and Functional Foods – October 02 – 05, 2022 – Istanbul

Roskilde October 5, 2022

CEO Anders Christesen presented the talk

The development of an enteric capsule made from natural materials for oral delivery of Probiotics / Nutraceuticals”

at the  14th International Conference and Exhibition on Nutraceuticals and Functional Foods – October 02 – 05, 2022 – Istanbul.

Apillet ApS Announces in-vitro testing of APIVault tablet Prototype.

Company announcement No. 01/2022

Roskilde, 10.06.2022

Apillet ApS Announces the in-vitro testing of APIVault tablet Prototype.

Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the first prototype of the APIVault enteric technology for targeted delivery in the small intestine and the colon.

The APIVault encapsulation material is produced solely from natural materials with a combination of bacterial cellulose and cellulases as basis. The prototype is a tablet protecting the enclosed substance against enzymatic degradation and low pH in the stomach. The tablets can be programmed to release the substance at a predetermined location in the small intestine or in the colon.

Apillet has through recent development work obtained further knowledge of the protection properties, release properties and design parameters of APIVault. A formula for targeted release at locations in the small intestine and the colon has been designed. Furthermore, prototypes have been produced.

We are now testing the release properties of a model substance to further validate the APIVault. We are looking for first candidate Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics or Nutraceuticals to test release properties in-vitro and in-vivo.

About APILLET ApS

Apillet ApS, (CVR-no. 41388285) is a biotech company based in Roskilde Denmark, that develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.

Further information:

CEO Anders B. Christensen, cell +45 5178 0684, email: anders.christensenapillet.com

CFO Carsten L. Petersen, cell +45 2346 2718, email: carsten.petersenapillet.com

 

Apillet ApS

Ternevej 45

4000 Roskilde, Denmark

CVR. 39601230

Advisor

Virkon ApS

Gammel Kongevej 11

1610 København

Danmark

Skype ID: virkon.dk

virkon@virkon.dk

CVR: 33507798

New data on APIVaults release functionality

Roskilde October 21. 2021

The encapsulation retains the payload until a well-defined percentage of the BC membrane has been digested by the cellulase. When this digestion threshold has been reached there is a sudden change in permeability and the payload is fully released over a short span of time. This release pattern can be explained by a phenomenon known in materials science as percolation. New in vitro data defines narrow boundaries on the percolation threshold of the BC membrane.

The release pattern provides excellent opportunities for controlling the entestinal site of release together with opportunities for controlling the time window for release.

This substantiates that the ApiVault Technology can deliver targeted release of probiotics, prebiotics, nutraceuticals, enzymes, biologics, peptides and small molecules in predestined segments of the intestine.